Physician profile
Robert Theiss
NPI 1699174680
$4,854.27
in general payments reported to CMS, 2019-2025
29 companies · $979 in 2025
The $979 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $494 · 2021: $406 · 2022: $467 · 2023: $552 · 2024: $1,085 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320 · Travel and Lodging: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.05 |
| Travel and Lodging | $296.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $593.11 | 2024 | Xeomin |
| Abbott Laboratories | $591.51 | 2024-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $477.30 | 2019-2025 | General - Therapies, General - Pain Management, Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $455.27 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $446.50 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Janssen Pharmaceuticals, INC | $372.83 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $256.55 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $169.48 | 2019-2023 | Camzyos |
| Allergan, INC. | $159.42 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $158.15 | 2019-2024 | Ultomiris |
| Melinta Therapeutics, LLC | $153.02 | 2021-2024 | Orbactiv, Kimyrsa, Rezzayo |
| Astrazeneca Pharmaceuticals Lp | $135.37 | 2020-2021 | |
| Globus Medical, INC. | $125.88 | 2025 | Senza |
| Medtronic, INC. | $119.46 | 2024 | Synchromedii |
| Inari Medical, INC. | $109.07 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $99.67 | 2021-2023 | Teflaro |
| Otsuka America Pharmaceutical, INC. | $86.29 | 2019 | |
| Amgen INC. | $58.81 | 2022-2023 | Repatha |
| Smith+Nephew, INC. | $51.52 | 2022 | |
| Pfizer INC. | $38.25 | 2019-2021 | |
| Bioxcel Therapeutics, INC. | $32.67 | 2023 | Igalmi |
| Janssen Scientific Affairs, LLC | $30.36 | 2023 | Xarelto |
| Tetraphase Pharmaceuticals, INC. | $29.62 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $27.44 | 2021 | |
| Portola Pharmaceuticals, LLC | $22.76 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.13 | 2019 | |
| Incyte Corporation | $15.44 | 2023 | Jakafi |
| Vifor Pharma, INC. | $13.24 | 2019 | |
| Biomerieux INC | $8.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Theiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.